×
About 6,528 results

ALLMedicine™ Herpes Zoster Center

Research & Reviews  1,714 results

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practic...

Baricitinib demonstrates consistent long-term safety profile in RA
https://www.mdedge.com/rheumatology/article/249281/rheumatoid-arthritis/baricitinib-demonstrates-consistent-long-term

Dec 1st, 2021 - Key clinical point: Baricitinib maintained a stable safety profile with no new safety signals even with long-term exposure of up to 9. 3 years in patients with active rheumatoid arthritis (RA).

Risk of Herpes Zoster Reactivation After mRNA COVID-19 Vaccination: A Cohort Study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608757
Journal of the American Academy of Dermatology; Birabaharan M, Kaelber DC et. al.

Nov 27th, 2021 - Risk of Herpes Zoster Reactivation After mRNA COVID-19 Vaccination: A Cohort Study.|2021|Birabaharan M,Kaelber DC,Karris MY,|

Plantar fascial fibromatosis and herpes zoster.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612523
PloS One; Hsu CY, Ke DS et. al.

Nov 25th, 2021 - Infection, chronic pain and depression are considered risk factors for herpes zoster (HZ). However, the correlation between plantar fascial fibromatosis (PFF) and HZ remains unknown. This study investigated HZ risk in patients with PFF. Data was e...

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
https://clinicaltrials.gov/ct2/show/NCT01176006

Nov 24th, 2021 - Background Mutations in the Dedicator of Cytokinesis-8 (DOCK8) gene are responsible for an immunodeficiency disease characterized by: severe cutaneous and sinopulmonary infections with bacterial organisms; extensive cutaneous viral infections with...

see more →

Guidelines  3 results

Vaccines for measles, mumps, rubella, varicella, and herpes zoster: immunization guidel...
https://www.ncbi.nlm.nih.gov/pubmed/22086887
The Journal of the American Osteopathic Association; Hendriksz T, Malouf P et. al.

Dec 7th, 2011 - Although vaccinations are most commonly associated with the pediatric population, it is important for healthcare professionals to be familiar with the vaccines that are recommended for adults. The authors discuss 3 vaccines-the measles, mumps, and...

Interventional management of neuropathic pain: NeuPSIG recommendations.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484720
Pain References; Dworkin RH, O'Connor AB et. al.

Jun 12th, 2013 - Neuropathic pain (NP) is often refractory to pharmacologic and noninterventional treatment. On behalf of the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the authors evaluated systematic reviews, clinica...

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization ...
https://www.ncbi.nlm.nih.gov/pubmed/18528318
MMWR. Recommendations and Reports : Morbidity and Mortali... Harpaz R, Ortega-Sanchez IR et. al.

Jun 6th, 2008 - These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a live attenuated vaccine for the prevention of herpes zoster (zoster) (i.e., shingles) and its sequelae, which was licens...

see more →

Drugs  479 results see all →

Clinicaltrials.gov  53 results

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
https://clinicaltrials.gov/ct2/show/NCT01176006

Nov 24th, 2021 - Background Mutations in the Dedicator of Cytokinesis-8 (DOCK8) gene are responsible for an immunodeficiency disease characterized by: severe cutaneous and sinopulmonary infections with bacterial organisms; extensive cutaneous viral infections with...

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
https://clinicaltrials.gov/ct2/show/NCT05047770

Oct 20th, 2021 - The aim of this study is to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu...

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
https://clinicaltrials.gov/ct2/show/NCT05082688

Oct 19th, 2021 - Rationale: Vaccination of the older adults is often advised as they are a high-risk population; however, vaccine efficacy generally decreases with age. This is mainly due to a decrease in adaptive immune responses known as immunosenescence, which ...

Recombinant Zoster Vaccine in Stable SLE Patients
https://clinicaltrials.gov/ct2/show/NCT04516408

Oct 4th, 2021 - Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that requires long-term corticosteroid and/or immunosuppressive agents. Thus lupus patients are immunocompromised patients, and the incidence of herpes zoster is higher th...

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of th...
https://clinicaltrials.gov/ct2/show/NCT04176939

Sep 13th, 2021 - The purpose of this study is to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study will a...

see more →

News  355 results

Baricitinib demonstrates consistent long-term safety profile in RA
https://www.mdedge.com/rheumatology/article/249281/rheumatoid-arthritis/baricitinib-demonstrates-consistent-long-term

Dec 1st, 2021 - Key clinical point: Baricitinib maintained a stable safety profile with no new safety signals even with long-term exposure of up to 9. 3 years in patients with active rheumatoid arthritis (RA).

Slight Increase in Risk of Guillain-Barre After Recombinant Zoster Vaccine Confirmed
https://www.medscape.com/viewarticle/962005

Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...

Guillain-Barre Risk Up Slightly After Shingrix
https://www.medpagetoday.com/neurology/generalneurology/95364

Nov 1st, 2021 - Risk of Guillain-Barré syndrome (GBS) increased slightly after receiving the recombinant zoster vaccine (RZV; Shingrix), Medicare claims data showed. In the 42 days after vaccination, researchers found approximately three excess GBS cases per mill...

Upadacitinib Shows Potential for Ulcerative Colitis
https://www.medscape.com/viewarticle/961553

Oct 25th, 2021 - LAS VEGAS, Nevada — An oral Janus kinase 1 (JAK1) inhibitor upadacitinib (Rinvoq, AbbVie) showed high efficacy and good safety as a treatment for ulcerative colitis in a phase 3 trial. The finding could provide some reassurance after the US Food a...

ACIP Recommends Shingrix for Younger Immunocompromised Adults; Updates Pneumococcal Vaccine Guidance
https://www.medscape.com/viewarticle/961385

Oct 21st, 2021 - The US Centers for Disease Control and Prevention Advisory Committee of Immunization Practices (ACIP) has voted to recommend Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in immunodeficient or imm...

see more →

Patient Education  7 results see all →